Phase I/II trial of bendamustine, ixazomib, and dexamethasone in relapsed/refractory multiple myeloma

In this phase I/II trial, BID, bendamustine (70, 80, or 90 mg/m(2)), ixazomib (4 mg), and dexamethasone (40 mg), was administered to 28 patients with relapsed and/or refractory multiple myeloma (RRMM) exposed to bortezomib and lenalidomide and refractory to at least one. A 3 + 3 dose escalation base...

Descripción completa

Detalles Bibliográficos
Autores principales: Dhakal, Binod, D’Souza, Anita, Hamadani, Mehdi, Arce-Lara, Carlos, Schroeder, Katrina, Chhabra, Saurabh, Shah, Nirav N., Gauger, Katelyn, Keaton, Taylor, Pasquini, Marcelo, Hari, Parameswaran
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6663939/
https://www.ncbi.nlm.nih.gov/pubmed/31358733
http://dx.doi.org/10.1038/s41408-019-0219-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6663939/
https://www.ncbi.nlm.nih.gov/pubmed/31358733
http://dx.doi.org/10.1038/s41408-019-0219-3

Ejemplares similares